SLF1081851

Research use only, not for human use.

SLF1081851 is a Spns2 inhibitor. SLF1081851 inhibits S1P release with IC50 of 1.93 μM.

SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system.

——

Animal Model:C57BL/6 mice Dosage:20 mg/kg Administration:Intraperitoneal injection; blood was drawn 4 h postdose Result:Significantly decreased circulating lymphocyte count and plasma S1P concentration.Animal Model:Sprague Dawley mice (4-week-old) Dosage:10 mg/kg Administration:Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose Result:Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).

——

Others

Other Targets

LPL Receptor

——

——

2763730-97-6

343.51

C21H33N3O

>98% (HPLC)

In Vitro:?Ethanol : 10 mg/mL (29.11 mM; Ultrasonic)

CCCCCCCCCCc1ccc(cc1)-c1noc(CCCN)n1

——

(-20℃)

With Ice Pack

≥ 2 years